Annals of the Rheumatic Diseases

0 downloads 0 Views 2MB Size Report
Jun 10, 2015 - E: [email protected] http://group.bmj.com/group/advertising. Display & Online Advertising Sales (USA). Jim Cunningham. T: +1 201 767 4170.
June 2015 Volume 74 Supplement 2

Annals of the Rheumatic Diseases The EULAR Journal

Annual European Congress of

RHEUMATOLOGY EULAR 2015 Italy, 10–13 June 2015

Abstracts

ard.bmj.com

eular

Editor Tore K Kvien (Norway) Associate Editors Francis Berenbaum (France) Hans Bijlsma (The Netherlands) David Pisetsky (USA) Dimitrios Boumpas (Greece) Gerd Burmester (Germany) Mary Crow (USA) Iain McInnes (UK) Methodological Adviser Stian Lydersen (Norway) Statistical Advisor Maarten Boers (The Netherlands) Social Media Advisors Elena Nikiphorou (UK) Meghna Jani (UK) Mary Canavan (Ireland)

Guidelines for Authors and Reviewers Full instructions are available online at ard.bmj.com/ifora. Articles must be submitted electronically at http://mc.manuscriptcentral.com/ard. Authors retain copyright but are required to grant ARD an exclusive licence to publish.

ARD Online Archive The full back archive of ARD is now available from 1969 at ard. bmj.com. Users have FREE access to all articles, older than 12 months*, right back to Volume 1, Issue 1. The online archives were digitised with the help of the US National Library of Medicine. Personal subscribers must sign in to access this content. Users not covered by an institutional or personal subscription will have to complete a one-time registration that grants access to all archive content, across all our titles. *Articles that are 12 months old or less require a subscription to access them.

Annals of the Rheumatic Diseases publishes original work on all aspects of rheumatology and disorders of connective tissue. Laboratory and clinical studies are equally welcome Editorial Board Daniel Aletaha (Austria) Maarten Boers (The Netherlands) Matthew Brown (Australia) Loreto Carmona (Spain) Carlo Chizzolini (Switzerland) Bernard Combe (France) Philip Conaghan (UK) Maurizio Cutolo (Italy) László Czirják (Hungary) Nicola Dalbeth (New Zealand) Oliver Distler (Switzerland) Thomas Dörner (Germany) Gary Firestein (USA) David Fox (USA) Sherine Gabriel (USA) Mary Goldring (USA) Juan Gómez-Reino (Spain) Walter Grassi (Italy) Wolfgang Gross (Germany) Francis Guillemin (France) Ahmet Gül (Turkey) Kåre Birger Hagen (Norway) Frederic Houssiau (Belgium) Tom Huizinga (The Netherlands) Roland Jonsson (Norway) George Kollias (Greece) Robert Landewé (The Netherlands) Zhan-Guo Li (China) Rik Lories (Belgium) Ingrid Lundberg (Sweden) Gary MacFarlane (UK) Xavier Mariette (France)

Alberto Martini (Italy) Wlodzimierz Maslinski (Poland) Marco Mattuci Cerinic (Italy) Pier-Luigi Meroni (Italy) Pierre Miossec (France) Mike Nurmohamed (The Netherlands) Monika Østensen (Switzerland) Mikkel Østergaard (Denmark) Constatino Pitzalis (UK) Berent Prakken (The Netherlands) Lars Rönnblom (Sweden) Jane Salmon (USA) Georg Schett (Germany) José da Silva (Portugal) Hendrik Schulze-Koops (Germany) Nan Shen (China) Alexander So (Switzerland) Tuulikki Sokka (Finland) Deborah Symmons (UK) Tsutomu Takeuchi (Japan) Alan Tyndall (Switzerland) John Varga (USA) Dimitrios Vassilopoulos (Greece) Douglas Veale (Ireland) Jiri Vencovsky (Czech Republic) Ronald van Vollenhoven (Sweden) Michael Ward (USA) Kevin Winthrop (USA) Kazuhiko Yamamoto (Japan) Editor, BMJ

Advisory Committee Wim van den Berg (The Netherlands) Stefano Bombardieri (Italy) Ferdinand Breedveld (The Netherlands) Leslie Crofford (USA) Michael Doherty (UK) Maxime Dougados (France) Paul Emery (UK) Daniel Furst (USA) Steffen Gay (Switzerland) Désirée van der Heijde (The Netherlands) Marc Hochberg (USA) Joachim Kalden (Germany) Edward Keystone (Canada) Lars Klareskog (Sweden) Peter Lipsky (USA)

Stefan Lohmander (Sweden) Sir Ravinder Maini (UK) Emilio Martín-Mola (Spain) Haralampos Moutsopoulos (Greece) James O’Dell (USA) Karel Pavelka (Czech Republic) Leo van de Putte (The Netherlands) Jozef Rovensky (Slovakia) Yehuda Shoenfeld (Israel) Josef Smolen (Austria) Walther van Venrooij (The Netherlands) Michael Weinblatt (USA) Frank Wollheim (Sweden) Anthony Woolf (UK)

Subscription Information ARD is published monthly; subscribers receive all supplements ISSN 0003-4967 (print); 1468-2060 (online)

Institutional Rates 2015

Personal Rates 2015

Print £851; US$1660; €1149

Print (includes online access at no additional cost) £350; US$683; €683

Online

Online only £148; US$289; €200

Site licences are priced on FTE basis and allow access by the whole institution. Details available online at http://group.bmj.com/group/subs-sales or contact the Subscription Manager in the UK (see above right)

Eular congress delegates Delegates to the annual Eular congress receive a free 12 month print subscription

Personal print or online only and institutional print subscriptions may be purchased online at http://group.bmj.com/group/ subs-sales (payment by Visa/Mastercard only) Residents of some EC countries must pay VAT; for details, call us or visit www.bmj.com/subscriptions/vatandpaymentinfo.dtl

Contact Details Editorial Office Annals of the Rheumatic Diseases BMJ Publishing Group Ltd BMA House Tavistock Square London WCIH 9JR,UK T: +44 (0)20 7383 6250 E: [email protected] Permissions http://group.bmj.com/group/rights-licensing/ permissions Supplement Enquiries T: +44 (0)20 7383 6057 E: [email protected] For ALL subscription enquires and orders T: +44 (0)20 7111 1105 E: [email protected] http://ard.bmj.com/site/help/index.xhtml Display Advertising Sales Mark Moran (Sales Manager) T: +44 (0)20 7383 6783 E: [email protected] http://group.bmj.com/group/advertising Online Advertising Sales Marc Clifford (Sales Manager) T: +44 (0) 20 7383 6161 E: [email protected] http://group.bmj.com/group/advertising Display & Online Advertising Sales (USA) Jim Cunningham T: +1 201 767 4170 E: [email protected] Author Reprints Reprints Administrator T: +44 (0)20 7383 6305 E: [email protected] Commercial Reprints (except USA & Canada) Nadia Gurney-Randall T: +44 (0)20 8445 5825 M: +44 07866 262344 E: [email protected] Commercial Reprints (USA & Canada) Marsha Fogler PO Box 3227 Cherry Hill, NJ 08034, USA T: +1 800 482 1450 (toll free in the USA) T: +1 856 489 4446 (outside the USA) E: [email protected] EULAR Eular Executive Secretariat Seestrasse 240, 8802 Kilchberg, Switzerland E: [email protected] www.eular.org

978 AB0258

Scientific Abstracts PREDICTORS OF MALADAPTIVE COPING STRATEGIES IN PATIENTS WITH RHEUMATOID ARTHRITIS

E.V. Muslimova, S.P. Yakupova, E.Z. Yakupov. Therapeutic, Kazan State Medical University, Kazan, Russian Federation Background: The use of maladaptive coping strategies in patients with rheumatoid arthritis (RA) associates with disability, psychological distress and high pain intensity. Identifying the predictors of maladaptive coping could help physicians in revealing the target group of patients which requires the conducting of the cognitive - behavioral therapy. Objectives: To identify the predictors of maladaptive coping strategies in patients with RA. Methods: The cross-sectional survey included 124 patients with RA (male to female ratio 4,4:1), mean age 49,4 [44; 56] years, mean duration of disease ranged from 3 months to 41 years (10,8 [3,5;13]). RA diagnosis based on ACR/EULAR criteria of 2010. Patients completed the following questionnaires: Visual - Analogue Scale (VAS), Beck Depression Inventory, State-Trait Anxiety Inventory, McGill Pain Questionnaire, The Pain Catastrophizing Scale. To identify the predictors of maladaptive strategies a logistic regression model was constructed (R2=0,694, p1.2 or >0.6 if DAS28≥3.2 (2). The annual flare rate was calculated as the number of flares divided by disease duration. Other important characteristics of RA and risk factors for CVD were determined at baseline or during follow-up. Characteristics of cases and controls were compared by unpaired t-tests or Mann-Whitney U. Logistic regression was performed to determine the crude association between the annual flare rate and occurrence of MI. Confounding variables were taken into account in multivariate logistic regression. Variables were identified as confounders if their inclusion in the model changed the coefficient (B) of annual flare rate with ≥10%. Results: The study population consisted of 41 cases and 181 matched controls. The proportion of men differed significantly between cases (51%) and controls (31%). Mean age at MI event was significantly higher than age at censoring. Furthermore, risk factors for CVD were raised in cases, like significantly higher BMI, total cholesterol, triglyceride, LDL, atherogenic index, incidence of hypertension and, a significantly lower HDL, compared to controls. Other characteristics like smoking status, disease duration, average DAS28, rheumatoid factor, C-reactive protein, incidence of diabetes mellitus and medication use did not differ significantly between cases and controls. The crude OR of the annual flare rate and the occurrence of MI was 0.78 (95% CI: 0.48; 1.25). The OR adjusted for age, LDL, male gender, cholesterol, hypertension, and HDL was 0.97 (95% CI: 0.58; 1.68). Conclusions: In contrast to expectations, no significant association was found between annual flare rate and the occurrence of MI in RA patients. This suggests that there is no large influence of flares in disease activity on incidence of MI in RA patients. Limitations that might cause bias include issues in definition of flare, and limited precision. References: [1] Radovits BJ, Popa-Diaconu DA, Popa C, Eijsbouts A, Laan RF, van Riel PL, et al. Disease activity as a risk factor for myocardial infarction in rheumatoid arthritis. Annals of the rheumatic diseases. 2009;68(8):1271-6. [2] van der Maas A, Lie E, Christensen R, Choy E, de Man YA, van Riel P, Woodworth T, den Broeder AA. Construct and criterion validity of several proposed DAS28-based rheumatoid arthritis flare criteria: an OMERACT cohort validation study. Ann Rheum Dis. 2013 Nov;72(11):1800-5. Disclosure of Interest: None declared DOI: 10.1136/annrheumdis-2015-eular.3470

AB0261

DRUG SURVIVAL AND THE ASSOCIATED PREDICTORS AMONG PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING TACROLIMUS

E.K. Park 1 , S.G. Lee 1 , D.W. Koo 1 , G.T. Kim 2 , J.W. Lee 3 . 1 Division of Rheumatology, Department of Internal Medicine, Pusan National University Hospital; 2 Division of Rheumatology, Department of Internal Medicine, Kosin University College of Medicine; 3 Division of Rheumatology, Department of Internal Medicine, Busan St. Mary’s Hospital, Busan, Korea, Republic Of Background: Drug survival can be considered as a composite measure of efficacy and safety in clinical practice. Although the drug survival rate of biologic agents in the treatment of rheumatoid arthritis (RA) has recently been extensively studied, only few studies have examined the drug survival rate for tacrolimus (TAC) in such cases. Objectives: The present study aimed to investigate the drug survival rate of TAC in the treatment of RA and to analyse the potential predictors of this rate in routine clinical care. Methods: In this retrospective longitudinal study, we enrolled 102 RA patients treated with TAC for at least 1 year from April 2009 to January 2014 at a tertiary centre in South Korea. The causes of TAC discontinuation were classified as lack of efficacy (LOE), adverse events (AEs), and others (patient or medical decision and miscellaneous). The drug survival rate was estimated using the Kaplan-Meier method and the predictors of this rate were identified by Cox-regression analyses. Results: TAC was discontinued in 27 of 102 RA patients (26.5%), after a mean duration of 34.1 months; the number of TAC discontinuations due to LOE, AEs, and others was 15 (14.7%), 11 (10.8%) and 1 (1%), respectively. The 2-year survival rate for TAC was 78.3% (Figure 1). Multivariable Cox-regression models indicated that compared to RA patients with low or moderate disease activity (Disease Activity Score 28-erythrocyte sedimentation rate [DAS28-ESR] ≤5.1), RA patients with high baseline disease activity had a significantly higher risk of TAC discontinuation, regardless of the cause (HR=2.49; 95% CI=1.16-5.35, p=0.019), or specifically, due to LOE (HR=3.55; 95% CI=1.25-10.09, p=0.02). Moreover, younger age (